Figure 3

Relapse-free survival of stage II and III CRC patients, based on CXCL8 expression within the tumour inflammatory infiltrate. Kaplan–Meier curve representing the recurrence-free survival of stage II and stage III colorectal cancer patients. Samples were stratified on the basis of either positive or negative CXCL8 immunoreactivity within the infiltrating immune cells surrounding the tumor epithelium. Patients with a CXCL8 positive infiltrate were shown to have an increased relapse-free survival with the median interval not being reached. In contrast, patients with no CXCL8 immunoreactivity had a median survival of 69 months (P<0.01; log-ranks test).